Intracellular Ca^2+^ signals critically control a plethora of cellular functions, of which many impact cellular death and/or survival, processes often dysregulated in cancer [@B1]. In healthy cells, Ca^2+^ signaling is employed for normal cell physiology and survival functions [@B2]. Yet, when a cell is exposed to toxic stimuli or suffering from enduring cell stress, like irreparable DNA damage, the Ca^2+^-signaling toolbox can be rapidly switched from a \"pro-survival\" modus into a \"pro-death\" modus, thereby initiating demise pathways [@B3]. The highly dynamic nature of Ca^2+^ signaling allows cells to swiftly response to stress and damage, preventing the survival of damaged cells and malignant transformation that eventually results in tumor formation. Alterations in the expression, activity and regulation of Ca^2+^-transport systems both at the plasma membrane and at organelles like the endoplasmic reticulum (ER) and mitochondria have been implicated in oncogenesis and neoplasia [@B1][@B4]. These changes result in aberrant Ca^2+^-signaling events that could favor resistance to cell death, migration or senescence escape [@B5].

Over the last decade, we learnt that tight contacts and functional connections involving Ca^2+^ exchanges between the ER, the main intracellular Ca^2+^-storage organelle, and the mitochondria are pivotal for cell-fate decisions [@B3][@B6][@B7][@B8]. These contact sites contain chaperone-coupled Ca^2+^-flux systems: the IP~3~ receptors (IP~3~Rs) at the ER side and the voltage-dependent anion channels (VDACs) at the mitochondrial outer membrane side [@B9]. These are controlled/exploited by several cellular factors and regulatory proteins, including oncogenes and tumor suppressors [@B10][@B11][@B12]. Basal Ca^2+^ fluxes between ER and mitochondria sustain anabolic pathways for mitochondrial metabolism, ensuring proper cell cycle progression [@B13]. Yet, continued elevated ER-mitochondrial Ca^2+^ transfers result in loss of mitochondrial membrane integrity and release of apoptogenic factors [@B14]. Tuned ER-mitochondrial Ca^2+^ transfer is therefore key to cells' response to pro-apoptotic stimuli: the failure of which results in cell death resistance, as often observed in cancer cells [@B15][@B16]. In fact, the efficacy of chemotherapeutic agents and photodynamic therapy depends on the ability of these agents to elicit ER-mitochondrial Ca^2+^ exchanges [@B15]. In the context of apoptosis, previous work proposed unique roles for the type 3 IP~3~R isoform (IP~3~R3) [@B17] and type 1 VDAC isoform (VDAC1) [@B18] even though other IP~3~R isoforms can contribute to the initiation of cell death programs [@B19][@B20].

In some cells, the role played by the IP~3~R3 in pro-apoptotic Ca^2+^ transfers from ER to mitochondria might relate to its ability to preferentially partner with the VDAC1 complex [@B18]. Notably, several tumor suppressors and oncogenes located at the ER membranes dodge ER Ca^2+^ homeostasis and dynamics [@B10][@B21]. In general, tumor suppressors increase ER-mitochondrial Ca^2+^ fluxes, whereas oncogenes suppress ER-mitochondrial Ca^2+^fluxes. The actions of both tumor suppressors and oncogenes at the ER can involve changes of the steady-state ER Ca^2+^-filling state through modulation of sarco/endoplasmic reticulum Ca^2+^ ATPases (SERCA) and/or ER Ca^2+^-leak channels. For instance, during stress, the tumor suppressor p53 accumulates at the ER and enhances the Ca^2+^-pump activity SERCA, causing ER Ca^2+^overload and the likelihood for pro-apoptotic ER-mitochondrial Ca^2+^fluxes [@B22][@B23][@B24]. The anti-apoptotic protein Bcl-2 increases IP~3~R phosphorylation and its sensitivity to IP~3~, enhancing the passive Ca^2+^ leak from the ER, lowering ER Ca^2+^ levels and so pro-apoptotic ER-mitochondrial Ca^2+^ fluxes [@B25]. Several tumor suppressors and oncogenes have been identified as direct regulators of the IP~3~R, whereby tumor suppressors (like BRCA1, PTEN, PML) and oncogenes (like Bcl-2, PKB/Akt) that respectively promote and suppress the activity of IP~3~R channels by impacting their gating and consequently their open probability [@B10][@B21]. Besides this direct regulation of IP~3~R gating, it is clear that total IP~3~R-protein levels impact Ca^2+^flux from the ER to the mitochondria and in turn cellular sensitivity to death as well. Insights are now available on IP~3~R degradation by ER-assisted and 26S proteasomal turnover after cell stimulation and IP~3~R activation [@B26]. In such conditions, IP~3~Rs become ubiquitinated due to recruitment of the erlin1/2 complex and RNF170, an E3 ubiquitin ligase [@B27][@B28][@B29].

Hitherto, not much was known about the molecular mechanisms impacting basal IP~3~R turn-over and controlling their steady-state in stressed cells; equally, whether dysregulation of these mechanisms was involved in oncogenesis and/or tumor progression. Nevertheless, it is clear that IP~3~R levels do impact apoptotic sensitivity [@B20][@B30][@B31][@B32], and hence cell death and survival proteins were found implicated in regulating IP~3~R levels [@B33][@B34].

Recent work from Kuchay *et al.* revealed an unexpected role for the tumor suppressor lipid/protein phosphatase PTEN, an allele frequently lost in cancer [@B35] and well-known negative regulator of PKB/Akt signaling, stabilizing IP~3~R channels by protecting them from proteasomal degradation [@B36] (**Fig. 1**). This novel function adds to its recently discovered presence at the mitochondria-associated membranes (MAMs), where it contributes to cell death sensitivity by suppressing IP~3~R3-mediated Ca^2+^ fluxes [@B37]. Independently of its catalytic activity, PTEN competes with the F-box protein FBXL2 (the receptor subunit of one of 69 human SCF (SKP1, CUL1, F-box protein) [@B38][@B39] to bind to IP~3~R3 channels, in particular to a region in the ligand-binding domain. Normal cells that express PTEN will have a low level of the IP~3~R3/FBXL2-complex formation, preventing the ubiquitination of IP~3~R3 channels and subsequent targeting to the proteasome. Consistently with previous observations [@B27][@B40], activation of cells with agonists increase FBXL2/IP~3~R3-complex formation and subsequent IP~3~R3 post-transcriptional regulation via ubiquitination similarly to RNF170-mediated ubiquitination of IP~3~Rs [@B27]. Interestingly, FBXL2 activity itself is Ca^2+^ dependent, but antagonized by calmodulin [@B41]. Hence, activation of IP~3~Rs may not only make these channels more susceptible for degradation by increased interaction with FBXL2 but release of Ca^2+^ itself through IP~3~Rs may trigger local activation of FBXL2 associated with IP~3~R3 leading to IP~3~R3 degradation. Notably, FBXL2 binding to its substrates (like cyclin D3) was found to occur via canonical calmodulin-binding motif thereby preventing ubiquitination. It is nonetheless likely that FBXL2 binding to IP~3~Rs does not occur by targeting its calmodulin-binding motif even though a role for calmodulin in regulating IP~3~R3/FBXL2-complex formation may not be ruled out. In any case, access to the degron region in the ligand-binding core of IP~3~R3 for FBXL2 is facilitated by deletion of the suppressor domain and loss of PTEN is associated with increased FBXL2 binding to IP~3~R3 and degradation of IP~3~R3, contributing to the apoptotic resistance of cells [@B36]. In cancer cells lacking PTEN, FBXL2 knockdown could therefore restore IP~3~R3 levels and apoptotic sensitivity.

![FIGURE 1: IP~3~R3 channels are targets for ubiquitination and deubiquitylation enzymes, whose activities are deregulated in cancer cells, thereby impacting IP~3~R3 stability and ultimately cell death sensitivity.\
**(A)** IP~3~Rs, located at the ER-mitochondrial interface, here particularly IP~3~R3, promote ER-mitochondrial Ca^2+^ fluxes, thereby enabling adequate cell death sensitivity in healthy cells undergoing genotoxic stress and cell damage, an important feature that prevents oncogenesis. The levels of IP~3~R3 channels are critical for this process and are dynamically regulated via ubiquitination. BAP1, a tumor suppressor with deubiquitylation enzyme activities and frequently mutated in cancers including mesothelioma, deubiquitylates IP~3~R3, preventing its proteasomal degradation and resulting in IP~3~R3 stabilization. In contrast, FBXL2, an F-Box protein with ubiquitin ligase activity, ubiquitinates IP~3~R3, directing it for proteasomal degradation and resulting in a decline in IP~3~R3 levels. Importantly, PTEN, another tumor suppressor that antagonizes Akt signaling and frequently mutated in a variety of cancers including prostate cancer, competes with FBXL2 for IP~3~R3 binding and thus antagonizes FBXL2-mediated ubiquitination of IP~3~R3, stabilizing IP~3~R3. In healthy cells, it is anticipated that the balance between deubiquitylation and ubiquitination of IP~3~R3 channels is favored towards deubiquitylated IP~3~R3, enabling sufficient IP~3~R3 channels to sustain adequate ER-mitochondrial Ca^2+^ fluxes in cells undergoing genotoxic stress and cell damage to engage cell death and eradicate pre-malignant cells with DNA damage.\
**(B)**Several cancer types display chromosomal aberrations with defects in the expression of several tumor suppressors, including a reduction in BAP1 levels and a loss in PTEN expression. As a consequence, both alterations will favor IP~3~R3 ubiquitination and degradation, since reduced BAP1 levels will lead to reduced deubiquitylation of IP~3~Rs and loss of PTEN will enable FBXL2 to mediate IP~3~R3 ubiquitination. As a consequence, the balance between ubiquitination and deubiquitylation of IP~3~R3s will shift towards ubiquitinated IP~3~R3, impairing ER-mitochondrial Ca^2+^ fluxes that are needed to engage cell death programs in response to genotoxic stress and cell damage. As such, cells will be able to withstand this cellular stress, resulting in their survival and proliferation despite accumulated DNA damage. This phenomenon is an early event in oncogenesis, enabling malignant cell formation and tumoral behavior.](ces-01-073-g01){#Fig1}

Notably, authors show that by mutating the degron region in the ligand-binding domain in IP~3~R3 the FBXL2 binding and IP~3~R3 degradation were both prevented. Using a knockin approach in which wild-type IP~3~R3 was altered into a non-degradable IP~3~R3 mutant version (IP~3~R3^Q550A/F553A/R554A^), the authors could restore the rise of Ca^2+^ induced by photodynamic therapy and apoptosis in PTEN-negative cancer cells. This correlation was eloquently observed in human tumor samples beyond the convincing *in vivo* xenograft models, in which tumor cells expressing a non-degradable IP~3~R3 version or treated with geranylgeranyltransferase inhibitor (that prevents FBXL2 accumulation at ER membranes and activity, which depends on its geranylgeranylation [@B42]) were greatly sensitized towards photodynamic therapy compared to tumor cells expressing wild-type (degradable) IP~3~R3 or untreated tumors.

It is important to note that FBXL2 has been previously implicated in cancer, but rather acting via the suppression of cell cycle progression and proliferation, as observed in lung tumors [@B43], leukemic cells [@B44], gastric cancer cells [@B45], and prevalently of tumor suppressive nature. Instead, in this work, the effects of FBXL2 on IP~3~R3 are tumor promoting by increasing IP~3~R3 degradation and making the cells more resistant to cell death [@B36]. These effects are neutralized by PTEN, which prevents FBLX2 binding to IP~3~R3 channels. This interference by PTEN is likely selective for IP~3~R3 and not for other FBXL2 targets regulating the cell cycle. Nevertheless, the anti-cancer properties of FBXL2 activators like the small molecule BC-1258 [@B46] will be adversely impacted by FBXL2-mediated IP~3~R3 degradation, likely limiting their application to PTEN-positive cancers. Vice versa*,* the previously discovered tumor suppressive properties of FBXL2 in cancer might be further boosted if FBXL2 could be selectively/subcellularly activated to pro-mote its cell-cycle targets while shielding IP~3~R3 for degradation.

In a separate study, Bononi *et al*. revealed a novel deubiquitylating enzyme that actually counteracts the level of IP~3~R3 ubiquitination, namely BRCA-associated protein 1 (BAP1) [@B47] (**Fig. 1**). BAP1 is a potent tumor suppressor, which protects against environmental stress and damage [@B48]. Loss of one BAP1 allele either inherited or acquired during life has been associated with environmental stress-induced carcinogenesis, like UV light for uveal melanoma and asbestos for mesothelioma. Germline mutations in BAP1 resulting in aberrant/loss of BAP1 expression were associated with a high incidence of familial mesothelioma and uveal melanoma, while somatic mutations in BAP1 were found in sporadic mesotheliomas [@B49]. Germline mutations in BAP1 greatly enhanced the sensitivity of mice to develop mesothelioma when exposed to asbestos [@B50]. Recently, it has been shown in patient fibroblasts that loss of BAP1 displayed a metabolic rewiring towards aerobic glycolysis and reduced mitochondrial respiration associated with malignancy and carcinogenesis [@B51]. BAP1 was therefore identified as a novel IP~3~R3-interacting protein that impacts its post-translational modification. BAP1 causes IP~3~R3 stabilization and prevents the channel to be degraded by the proteasome. Loss of only 1 allele in BAP1 is sufficient to protect cells from undergoing apoptotic cell death via suppressed Ca^2+^ release triggered by apoptotic stimuli like H~2~O~2~. An effect operated via the IP~3~R3 degradation due to a decreased BAP1-mediated deubiquitylation of IP~3~R3. As a consequence, exposure of cells being BAP1^+/-^ to DNA-damaging conditions will result in a higher percentage of cells surviving despite having damaged DNA. Such cells bearing genomic aberrations are at high risk for neoplastic behavior and oncogenesis, resulting in malignant cell growth and tumor formation. However, restoring IP~3~R3 in these cells could be an attractive strategy to reinstate cell death sensitivity of BAP1^+/-^ cells.

Based on these recent developments, it will be therefore important to examine the interplay between BAP1 and FBXL2. It is indeed not clear whether the increased IP~3~R3 ubiquitination observed when BAP1 levels are declined is mediated through FBXL2 and whether lack of BAP1 results in increased FBXL2 association with IP~3~R3 channels. In any case, by inhibiting FBXL2's action on IP~3~R3 without inhibiting its action on cell cycle targets could be an attractive avenue to restore IP~3~R3 levels in these cancers. Another strategy can be boosting ER Ca^2+^-store loading in tumor cells by activating the SERCA pumps, thereby increasing the likelihood for ER-mitochondrial Ca^2+^ fluxes and restoring cellular sensitivity to apoptosis [@B22][@B52]. Tumor-selective SERCA modulation is challenging but not impossible though, as evidenced by the ability to locally release thapsigargin in the vicinity of pancreatic tumor cells using peptide-coupled prodrugs that are enzymatically cleaved by prostate-specific factors [@B53]. SERCA-activating approaches may be based on p53, recently proposed to activate SERCA activity in response to chemotherapy [@B22][@B23][@B24], although p53 is very frequently mutated in cancer. In wild-type p53 tumors, direct p53 activators might be of use. Other solace may come from SERCA-activating small molecules like CDN1163 [@B54], provided these agents can be delivered to tumor cells while sparing healthy cells [@B52].

These recent papers highlight that deregulation of IP~3~R3 ubiquitination homeostasis not only impacts death and survival of cells but also contributes to the oncogenic behavior of cells with dysfunctional tumor suppressors by either (i) lacking PTEN [@B36] or by (ii) displaying deficiencies in BAP1 [@B47]. They underpin the emerging role of altered Ca^2+^signaling at the MAM level as a key event in apoptosis resistance that contributes early events associated with oncogenesis and tumor formation. Challenging will be the translation of these insights into anti-cancer therapies for which not only tumor-selective applications will be required but also further understanding in the selective targeting at the level of the IP~3~R3.
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